Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,424.85 162.29 1.00%
S&P 500 1,862.31 19.33 1.05%
NASDAQ 4,086.22 52.06 1.29%
Ticker Volume Price Price Delta
STOXX 50 3,139.26 47.74 1.54%
FTSE 100 6,584.17 42.56 0.65%
DAX 9,317.82 144.11 1.57%
Ticker Volume Price Price Delta
NIKKEI 14,417.68 420.87 3.01%
TOPIX 1,166.55 30.46 2.68%
HANG SENG 22,696.01 24.75 0.11%

In the Fight Against Atrial Fibrillation, AtriCure Launches Maze IV Training Program in Europe



  In the Fight Against Atrial Fibrillation, AtriCure Launches Maze IV Training
  Program in Europe

Business Wire

AMSTERDAM, Netherlands -- October 1, 2013

AtriCure, Inc. (Nasdaq: ATRC), is partnering with leading atrial fibrillation
(Afib) centers and thought leaders across Europe to provide best-in-class
training on surgical ablation. The launch of an international Maze IV Training
program will take place on October 1 in Germany at Sana Stuttgart Cardiac
Surgery Center, one of six initial European hospitals selected to participate
in this important initiative. This initial course will be led by surgeons
recognized as experts in the field of surgical treatment for Afib. They
include:

  * James L. Cox, MD, professor of cardiac surgery at Washington University
    School of Medicine in St. Louis, Missouri, USA. Dr. Cox is recognized as
    the innovator of the Maze procedure and is primarily responsible for its
    origins in cardiac surgery.
  * Kai-Nicolas Doll, MD, chief of cardiac surgery at Sana Cardiac Surgery
    Center in Stuttgart, Germany.
  * Timo Weimar, MD, cardiac surgeon at Sana Cardiac Surgery Center in
    Stuttgart, Germany and international medical director of AtriCure.

Performed by a cardiothoracic surgeon, the Maze IV procedure uses an energy
source to create a “maze” of scar tissue on the heart that helps direct
electrical impulses to restore the heart’s normal rhythm. The procedure is
performed using AtriCure’s Synergy Ablation System which is CE Mark-approved
for use in Europe. AtriCure’s System is the only device shown to consistently
cure Afib in the most rigorous and demanding clinical trials.

"This is an extremely important initiative to ensure that patients who are
eligible for the Maze IV procedure receive it if they are undergoing another
heart procedure,” said Dr. Weimar. “It is a proven low risk, high cure
procedure. If more surgeons were trained on the proper technique, we could
make a significant impact in the incidence of Afib among our patients.”

As part of this initiative, AtriCure has formed a MAZE IV European Educational
Steering Committee to include luminaries in the area of surgical Afib ablation
from the following centers: OLVG Amsterdam, UZ Leuven Belgium; Hospital Clinic
of Barcelona, Spain; San Rafaelle University Hospital, Milan, Italy; and The
Royal College of Surgeons, London, England.

“By increasing awareness and treatment, this program will launch a greater
effort and serve as a model for other programs we have underway in a number of
centers internationally,” said Dr. Doll. “Along with AtriCure, we aim to curb
the potentially devastating physical and emotional impact Afib can have on
families, and the financial burden on society.”

Afib is the most common diagnosed arrhythmia, impacting 9.6 million Europeans.
People over the age of 40 have a one in four chance of developing Afib in
their lifetime, while those with Afib have a 500 percent greater risk of
stroke, heart failure and reduced quality of life than the general population.

“We are committed to reducing the global Afib epidemic and healing the lives
of those affected,” said Michael Carrel, president and CEO of AtriCure. “This
initiative is part of our core investment in education and clinical science to
bring better treatment options to patients in more parts of the world.”

About AtriCure, Inc.

AtriCure, Inc. is a leading atrial fibrillation solutions partner, providing
innovative products, professional education and support for clinical science
to reduce the economic and social burden of atrial fibrillation. AtriCure's
Synergy Ablation System is the first and only device approved by the Food and
Drug Administration (FDA) for the surgical treatment of Persistent and
Longstanding Persistent forms of Afib in patients undergoing certain open
heart procedures concomitantly (simultaneously). AtriCure's AtriClip™ Left
Atrial Appendage (LAA) occlusion device is the most widely implanted device
for LAA management worldwide. Afib affects more than two million people
worldwide and is estimated to cost more than $6.5 billion annually in
healthcare expenses. The number affected by Afib is expected to grow to 12
million by 2050.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995. Forward-looking
statements include statements that address activities, events or developments
that AtriCure expects, believes or anticipates will or may occur in the
future, such as earnings estimates, other predictions of financial
performance, launches by AtriCure of new products and market acceptance of
AtriCure’s products. Forward-looking statements are based on AtriCure’s
experience and perception of current conditions, trends, expected future
developments and other factors it believes are appropriate under the
circumstances and are subject to numerous risks and uncertainties, many of
which are beyond AtriCure’s control. These risks and uncertainties include the
rate and degree of market acceptance of AtriCure’s products, AtriCure’s
ability to develop and market new and enhanced products, the timing of and
ability to obtain and maintain regulatory clearances and approvals for its
products, the timing of and ability to obtain reimbursement of procedures
utilizing AtriCure’s products, competition from existing and new products and
procedures or AtriCure’s ability to effectively react to other risks and
uncertainties described from time to time in AtriCure’s SEC filings, such as
fluctuation of quarterly financial results, reliance on third party
manufacturers and suppliers, litigation or other proceedings, government
regulation and stock price volatility. AtriCure does not guarantee any
forward-looking statement, and actual results may differ materially from those
projected. AtriCure undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information, future
events or otherwise.

Contact:

AtriCure, Inc.
Andy Wade, 513-755-4564
Vice President and Chief Financial Officer
awade@atricure.com
OR
AtriCure Media Contact:
Rasor Marketing Communications
Becky Fickenworth, 1-513-793-1234
becky@rasormarketing.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement